

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-85 canceled.

86. (Previously presented) A method of performing a non-invasive ophthalmologic procedure *in vivo*, comprising:

providing a device that includes a pore forming portion, wherein the pore forming portion is coupled to a delivery portion and an optical portion;

using the pore forming portion to create an opening in a conjunctiva;

using the delivery portion to apply a clarifying agent through the opening to a sclera that is disposed below the conjunctiva;

wherein the clarifying agent enhances optical transparency of the sclera to thereby form an area of clarified sclera; and

using the optical portion non-invasively to deliver light from the optical portion positioned proximal to the conjunctiva or opening such that the light passes through the conjunctiva or opening to an area within or below the area of clarified sclera.

87. (Previously presented) The method of claim 86 wherein the pore forming portion and the optical portion are coaxially arranged relative to each other.

88. (Previously presented) The method of claim 86 wherein the optical portion comprises at least one of a confocal microscope and a device that provides spectral information from a fluid in the clarified sclera.

89. (Previously presented) The method of claim 86 wherein the pore forming portion employs mechanical force or laser irradiation to create the opening.

90. (Previously presented) The method of claim 86 wherein the clarifying agent is selected from the group consisting of diatrizoate meglumine acid, glycerol, and glucose.
91. (Previously presented) The method of claim 86 wherein the light is visible light.
92. (Previously presented) The method of claim 86 wherein the light is used for photocoagulation or photodynamic therapy.
93. (Canceled)
94. (Canceled)
95. (Canceled)
96. (Canceled)
97. (Canceled)
98. (Canceled)
99. (Canceled)
100. (Canceled)
101. (Previously presented) A method of performing a dermatological procedure *in vivo*, comprising:
 - providing a device that includes a pore forming portion, wherein the pore forming portion is coupled to a delivery portion and an optical portion;
 - using the pore forming portion to create an opening in a stratum corneum;
 - using the delivery portion to apply a clarifying agent through the opening to a tissue below the stratum corneum;
 - wherein the clarifying agent enhances optical transparency of the tissue below the stratum corneum to thereby form an area of clarified tissue;

wherein the pore forming portion and the optical portion are coaxially arranged relative to each other;

using the optical portion non-invasively at a position proximal to the stratum corneum to deliver visible light through the stratum corneum or the opening to an area within or below the area of clarified tissue such that the light passes through the stratum corneum to an area within or below the area of clarified tissue; and

wherein the device does not penetrate the stratum corneum and the tissue below the stratum corneum.

102. (Canceled)

103. (Previously presented) The method of claim 101 wherein the visible light has a wavelength of between 350 nm to 750 nm.

104. (Previously presented) The method of claim 101 wherein the clarifying agent is selected from the group consisting of diatrizoate meglumine acid, glycerol, and glucose.

105. (Previously presented) The method of claim 101 further comprising a step of applying to the stratum corneum an enhancing agent selected from the group consisting of a chemical enhancer, a carrier agent, and a penetrating solvent.